Frontline TIL Combination Shows Long Follow Up in Melanoma
Iovance’s final 24-patient Phase 2 cohort of lifileucel plus pembrolizumab in untreated advanced melanoma shows 62.5% confirmed response, 29.2% complete response, and median overall survival not reached after 50.9 months median study follow-up. Durability…
